Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Journal of the American College of CardiologyOpen Access

Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMatthew J. MaurerJBJohn L. BerkTDThibaud Damy

Discussion

Loading...

Member takes

Overview

Observational analysis shows that vutrisiran improves cardiac biomarkers in patients with transthyretin amyloidosis, suggesting potential for reduced mortality.

Key Points

  • Vutrisiran treatment resulted in significantly lower levels of NT-proBNP and troponin I compared to placebo after 30 months.
  • Increases in NT-proBNP and decreases in troponin I were linked to higher and lower risks of all-cause mortality, respectively.
  • The double-blind, placebo-controlled HELIOS-B study involved 655 patients with transthyretin amyloidosis and assessed various cardiac outcomes.
  • Biomarkers NT-proBNP and troponin I are crucial in predicting outcomes, highlighting the need for timely treatment initiation.

Cite This Study

Maurer et al. (2025) studied this question.

synapsesocial.com/papers/68c23dc5b210217d6478f68dhttps://doi.org/10.1016/j.jacc.2025.04.055
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial2025
  2. 2Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B Trial2026
  3. 3Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE‐CM, a Randomized Controlled Trial2026
  4. 4Amyloid-specific medication in transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis of cardiovascular outcome trials2025 · 1 citations
  5. 5Association of NT-proBNP With Clinical Outcomes in Patients Undergoing Transcatheter Tricuspid Valve Intervention2026